This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
